Simplified Enterprise Qualification under Disposición 8799/2025

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Disposición ANMAT 8799/2025 was published in the Official Gazette on November 28, 2025 and takes effect 60 administrative business days after publication. It offers enterprises engaged in the manufacturing and/or import of Class I and Class II medical devices and Group A and B IVD an optional simplified qualification channel: a sworn declaration (Declaración Jurada) submitted on the ANMAT digital platform replaces the traditional approval procedures of 2319/02 (T.O. 2004), 7425/13 and 2096/22.

Two boundaries must be held firmly: Class III/IV devices and Group C/D IVD are excluded and continue through the traditional procedures; and Good Manufacturing Practice obligations under Disposición 3266/2013 are not waived by the simplification — companies choosing this channel remain subject to subsequent ANMAT inspection. The channel streamlines the paperwork, never the standards behind it.

The channel is optional, not mandatory: an enterprise within scope may still prefer the traditional procedures, for example where its product portfolio spans risk tiers or where it expects frequent changes that would make declaration maintenance burdensome. What the instrument changes is the default cost of entry for low-risk players, not the underlying obligations that continue to apply once the enterprise is operating. The two boundaries — excluded risk tiers and preserved GMP duties — define exactly how far the simplification reaches, and both should be tested against the company’s actual portfolio before electing the channel.

2. Legal basis

The instruments below establish the simplified channel, the GMP obligations it preserves, the traditional procedures it replaces, and the penalties for false declarations.

InstrumentReference / numberPublication dateProvisions
Simplified channel for low-risk enterprise qualificationDisposición ANMAT 8799/2025Published November 28, 2025, effective 60 administrative business days after publicationScope provisions; sworn declaration content provisions; 30-day change notification provisions
Good Manufacturing Practices (BPF/GMP)Disposición ANMAT 3266/20132013GMP obligation preservation provisions
Authorization of operating qualification for manufacturing/import enterprisesDisposición ANMAT 2319/2002 (T.O. 2004)2002 (consolidated text 2004)Traditional procedure provisions
Enterprise qualification proceduresDisposición ANMAT 7425/2013; 2096/20222013 / 2022Traditional procedure provisions
National Health Products LawLey 16.463Enacted 1964, currently in forcePenalty provisions (false declarations)

3. Expert insights

Insight 1: the sworn declaration has no expiry date, but changes must replace it with a new declaration within 30 days. This is a distinctive design: the qualification itself carries no validity period, removing the recurring burden of renewals; however, any change to the company name, legal address, industrial premises, scope of activities, addition of warehouses or plants, or replacement of the Director Técnico requires a new sworn declaration within 30 days to replace the original. The regulatory logic shifts from periodic re-verification to declare-upon-change.

Insight 2: GMP obligations are expressly preserved — direct evidence that simplified does not mean relaxed. Companies choosing the channel must still implement 3266/13, retain compliance evidence, and accept ANMAT’s scheduled or unannounced inspections. ANMAT is shifting regulatory resources from review to inspection, and the probability of inspection rises in substance.

Insight 3: the transition rules for pending applications are tightly circumscribed. Where a qualification or change application is already pending when the instrument takes effect, the company must first complete all requirements under the existing procedure; only after completion and notification by ANMAT may it switch to the new channel. Once a new sworn declaration is submitted, the original file is deemed closed (except for matters involving Class III/IV and Group C/D IVD). This prevents program-hopping midway and the procedural confusion it would cause.

Electing the channel is easy; staying compliant under it is a standing operational commitment. The ongoing burden lies in change control — five trigger categories, each carrying its own 30-day filing clock — and in keeping GMP evidence continuously retrievable for inspection. The recommendations below turn those obligations into concrete mechanisms that survive personnel changes and portfolio growth alike.

4. Practical recommendations

  1. Apply the channel only to low-risk product lines. If the company also handles Class III/IV products, the traditional procedures still apply; consider splitting entities by product line before filing, or simply standardize on the traditional procedures to keep management simple.
  2. Build a trigger mechanism for the 30-day change filing. Treat name, address, premises, scope of activities and Director Técnico as five change triggers; whenever any of them changes, start preparing the new declaration immediately.
  3. Retain GMP compliance evidence as a standing practice. Facility and equipment maintenance, production process controls, cleaning and disinfection, material traceability, training records, and adverse event and recall procedures must be retrievable at any time.
  4. Watch the transition arrangements. Companies with pending applications should complete the existing procedure before switching and never file a new declaration while in the intermediate state.

5. Verification checklist

Confirm each item below before electing the 8799/2025 channel.

  • □ The scope of operations is limited to Class I/II devices and Group A/B IVD
  • □ The effective date of 8799/2025 — 60 administrative business days after publication — has been confirmed
  • □ A trigger mechanism for 30-day filings of the five change types is in place
  • □ GMP compliance evidence under 3266/2013 is retained on a standing basis
  • □ The transition rules for pending applications have been assessed
  • □ A verification workflow for the truthfulness of the sworn declaration content is defined

Re-test this checklist whenever the company’s structure changes — new premises, new legal addresses, new product lines or a new Director Técnico — since each of these events starts the 30-day filing clock on its own. A standing quarterly review of the declaration content is a simple, low-cost way to keep the qualification permanently accurate.

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and labeling localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the developments of regulatory authorities worldwide. All published content follows the drafting standard of conclusions first, traceable legal basis, and verifiable figures. For an Argentina or MERCOSUR market-access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail